220 related articles for article (PubMed ID: 15450343)
1. Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist.
Ruderman EM; Tambar S
Dermatol Clin; 2004 Oct; 22(4):477-86, x. PubMed ID: 15450343
[TBL] [Abstract][Full Text] [Related]
2. On the recurrence risk of arthritis among psoriatic patients.
Pedersen OB; Junker P
Scand J Rheumatol; 2009; 38(4):321-2. PubMed ID: 19308804
[No Abstract] [Full Text] [Related]
3. Psoriatic arthritis update.
Mease P
Bull NYU Hosp Jt Dis; 2006; 64(1-2):25-31. PubMed ID: 17121486
[TBL] [Abstract][Full Text] [Related]
4. [Psoriatic arthritis: what the dermatologist needs to know, Part 2].
López-Ferrer A; Torrente-Segarra V; Puig L
Actas Dermosifiliogr; 2010 Nov; 101(9):742-8. PubMed ID: 21034704
[TBL] [Abstract][Full Text] [Related]
5. Orthopedic manifestations and management of psoriatic arthritis.
Strauss EJ; Alfonso D; Baidwan G; Di Cesare PE
Am J Orthop (Belle Mead NJ); 2008 Mar; 37(3):138-47. PubMed ID: 18438469
[TBL] [Abstract][Full Text] [Related]
6. Five-year outcome of a primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis.
Morgan C; Lunt M; Bunn D; Scott DG; Symmons DP
Rheumatology (Oxford); 2007 Dec; 46(12):1819-23. PubMed ID: 18032539
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
Kristensen LE; Gülfe A; Saxne T; Geborek P
Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
[TBL] [Abstract][Full Text] [Related]
8. Psoriatic arthritis.
Holdsworth J
Nurs Stand; 2003 Oct 15-21; 18(5):47-52; quiz 54-5. PubMed ID: 14603767
[TBL] [Abstract][Full Text] [Related]
9. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
10. Psoriatic arthritis screening tools.
Qureshi AA; Dominguez P; Duffin KC; Gladman DD; Helliwell P; Mease PJ; Husni ME
J Rheumatol; 2008 Jul; 35(7):1423-5. PubMed ID: 18609737
[TBL] [Abstract][Full Text] [Related]
11. Development of a preliminary composite disease activity index in psoriatic arthritis.
Mumtaz A; Gallagher P; Kirby B; Waxman R; Coates LC; Veale J D; Helliwell P; FitzGerald O
Ann Rheum Dis; 2011 Feb; 70(2):272-7. PubMed ID: 21115550
[TBL] [Abstract][Full Text] [Related]
12. Etanercept for psoriasis in the pediatric population: experience in nine patients.
Hawrot AC; Metry DW; Theos AJ; Levy ML
Pediatr Dermatol; 2006; 23(1):67-71. PubMed ID: 16445417
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis.
Reich K; Krüger K; Mössner R; Augustin M
Br J Dermatol; 2009 May; 160(5):1040-7. PubMed ID: 19210498
[TBL] [Abstract][Full Text] [Related]
14. Psoriatic arthritis and arthroplasty: a review of the literature.
lofin I; Levine B; Badlani N; Klein GR; Jaffe WL
Bull NYU Hosp Jt Dis; 2008; 66(1):41-8. PubMed ID: 18333827
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis.
Gisondi P; Girolomoni G; Sampogna F; Tabolli S; Abeni D
Eur J Dermatol; 2005; 15(4):279-83. PubMed ID: 16048759
[TBL] [Abstract][Full Text] [Related]
16. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
18. [Prevalence of psoriatic arthritis in a population of patients with psoriasis].
Jajić Z; el Assadi G
Acta Med Croatica; 2003; 57(4):323-6. PubMed ID: 14639870
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey.
Radtke MA; Reich K; Blome C; Rustenbach S; Augustin M
J Eur Acad Dermatol Venereol; 2009 Jun; 23(6):683-91. PubMed ID: 19309433
[TBL] [Abstract][Full Text] [Related]
20. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept.
Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660
[No Abstract] [Full Text] [Related]
[Next] [New Search]
